Cooper Companies (COO) stock plummeted 5.39% in the intraday trading session on Friday, following mixed first-quarter results that prompted several analysts to lower their price targets and ratings on the medical device maker.
After reporting a revenue shortfall but an earnings beat for Q1 2025, Cooper Companies faced a wave of price target cuts from Wall Street firms. Citi lowered its target to $110 from $115 while maintaining a Buy rating, while Baird cut its target to $107 from $117 and reiterated an Outperform rating.
Morgan Stanley analysts maintained a Hold rating on the stock, noting challenges and opportunities ahead for the company. JPMorgan also trimmed its price target to $110 from $120 but kept an Overweight rating, while Needham reiterated a Hold stance, citing Cooper's mixed Q1 performance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。